Revenue Recognition - Schedule of Revenue by Product (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2018	Apr. 01, 2017
Disaggregation of Revenue [Line Items]
Net sales		$ 1,217.0	$ 1,194.0
CHCA
Disaggregation of Revenue [Line Items]
Net sales		601.6	582.8
CHCA | Cough/Cold/Allergy/Sinus
Disaggregation of Revenue [Line Items]
Net sales	[1]	141.5
CHCA | Infant Nutritionals
Disaggregation of Revenue [Line Items]
Net sales		103.4
CHCA | Analgesics
Disaggregation of Revenue [Line Items]
Net sales	[1]	93.7
CHCA | Gastrointestinal
Disaggregation of Revenue [Line Items]
Net sales	[1]	92.2
CHCA | Smoking Cessation
Disaggregation of Revenue [Line Items]
Net sales		65.9
CHCA | Animal Health
Disaggregation of Revenue [Line Items]
Net sales		26.3
CHCA | Vitamins, Minerals and Dietary Supplements
Disaggregation of Revenue [Line Items]
Net sales	[1]	3.0
CHCA | Other CHCA
Disaggregation of Revenue [Line Items]
Net sales	[1],[2]	75.6
CHCI
Disaggregation of Revenue [Line Items]
Net sales		401.4	374.9
CHCI | Cough, Cold, and Allergy
Disaggregation of Revenue [Line Items]
Net sales		98.7
CHCI | Lifestyle
Disaggregation of Revenue [Line Items]
Net sales		89.7
CHCI | Personal Care and Derma-Therapeutics
Disaggregation of Revenue [Line Items]
Net sales		75.6
CHCI | Natural Health and Vitamins, Minerals and Dietary Supplements
Disaggregation of Revenue [Line Items]
Net sales		33.2
CHCI | Anti-Parasite
Disaggregation of Revenue [Line Items]
Net sales		28.1
CHCI | Other CHCI
Disaggregation of Revenue [Line Items]
Net sales	[3]	76.1
RX
Disaggregation of Revenue [Line Items]
Net sales		$ 214.0	$ 217.4

[1] Includes net sales from our OTC contract manufacturing business.

[2] Consists primarily of branded OTC, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

[3] Consists primarily of liquid licensed products, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.